In recent years, especially in developed countries, there has been an increase in the incidence of pancreatic cancer. Only 20% of tumors at the time of diagnosis are evaluated as resectable, but in these cases, the prognosis of the disease is unfavorable. The overall 5-year survival rate does not exceed 5%.
Pancreatic cancer was described in the 1760s by Giovanni Battista Morgagni in his classic book “De Sedibus et Causis Morborum per Anatomen Indigatis”. Over the next 200 years, pathologists significantly improved our understanding of the macro- and microscopic features of this disease. At the same time, morphological research remained the basis of diagnostics for centuries. The introduction of immunohistochemical studies into clinical practice in the late 1970s and early 1980s radically changed our approach to diagnosing this disease. Evaluation of morphological features, as well as features of expression of markers that determine the invasive potential of such neoplasms, can serve in the future as a fundamental basis in solving questions concerning possible factors of prognosis upon malignant tumors of such a localization.
Aim of research — to study the morphological and immunohistochemical features of ductal pancreatic adenocarcinoma.
Materials and methods. The study included 84 patients with pancreatic cancer T1-4N0-2M0-1 stage, aged from 37 to 83, who underwent surgical treatment. Morphological study of the operating material was carried out. The condition for inclusion in the study was a histotype of the tumor, namely ductal pancreatic adenocarcinoma. Posting of the material, preparation of histological preparations, coloring, immunohistochemical examination were carried out according to a standard procedure.
Results and conclusion. The study made it possible to characterize the tumor morphology, as well as the features of expression of markers associated with more evident invasive characteristics of the tumor. The results of this work may be of interest in terms of their further comparison with the parameters of various forms of progression upon pancreatic cancer.
2. Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis / M. Principe, S. Borgoni, M. Cascione [et al.] // J. Hematol. Oncol. – 2017. – Vol. 10, No 1. – P. 16.
3. Anti-LRP/ LR-specific antibody IgG1-iS18 impedes adhesion and invasion of pancreatic cancer and neuroblastoma cells / T. M. Rebelo, C. J. Chetty, E. Ferreira, S. F. Weiss // BMC Cancer. – 2016. – Vol. 16, No 1. – P. 917.
4. Cancer invasion: patterns and mechanism / N. V. Krakhmal, M. V. Zavyalova, E. V. Denisov [et al.] // Acta Naturae. – 2015. – Vol. 7, No 2. – P. 17–28.
5. Clinical and pathological features of five-year survivors after pancreatectomy for pan-creatic adenocarcinoma / K. Kimura, R. Amano, B. Nahata [et al.] // World J. Surg. Oncol. – 2014. – Vol. 12. – P. 360.
6. Gerry J. M. Surgical Management of Pancreatic Cysts: A Shifting Paradigm Toward Selective Resection / J. M. Gerry, G. A. Poultsides // Dig. Dis. Sci. – 2017. – Vol. 62, No 7. – P. 1816–1826.
7. Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas / T. Zacharias, D. Jaeck, E. Oussoultzoglou [et al.] // J. Gastrointest. Surg. – 2007. – Vol. 11, No 3. – P. 350–356.
8. Lim J. E. Prognostic factors following curative resection for pancreatic adenocarcinoma : a population-based, linked database analysis of 396 patients / J. E. Lim, M. W. Chien, C. C. Earle // Ann. Surg. – 2003. – Vol. 237, No 1. – P. 74–85.
9. Long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma: is cure possible? / T. Schnelldorfer, A. L. Ware, M. G. Sarr [et al.] // Ann Surg. – 2008. – Vol. 247, No 3. – P. 456–462.
10. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer / H. Riediger, T. Keck, U. Wellner [et al.] // J. Gastrointest. Surg. – 2009. – Vol. 13, No 7. – P. 1337–1344.
11. The ratio of meta-static/resected lymph node is an independent prognostic factor in patients with node-positive pancreatic head cancer / M. Sierzega, T. Popiela, J. Kulig, K. Nowak // Pancreas. – 2006. – Vol. 33, No 3. – P. 240–245.
12. Siegel R. Cancer statistics, 2012 / R. Siegel, D. Naishadham, A. Jemal // CA Cancer J Clin. – 2012. – Vol. 62, No 1. – P. 10–29.
13. Topalovski M. Matrix control of pancreatic cancer: new insights into fibronectin signaling / M. Topalovski, R. A. Brekken // Cancer Lett. – 2016. – Vol. 381. – P. 252–258.
14. Weinberg B. A. Evolving standards of care for resected pancreatic cancer / B. A. Weinberg, P. A. Philip, M. E. Salem // Clin. Adv. Hematol. Oncol. – 2017. – Vol. 15, No 2. – P. 141–150.
15. WHO Classification of Tumours of the Digestive System / F. T. Bosman, F. Carneiro, R. H. Hruban, N. D. Theise // World Health Organization. – 2010. – 417 p.
16. Zuckerman D. S. Adjuvant therapy for pancreatic cancer : a review / D. S. Zuckerman, D. P. Ryan // Cancer. – 2008. – Vol. 112, No 2. – P. 243–249.